<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8804207</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1862</journal-id>
<journal-id journal-id-type="nlm-ta">Schizophr Res</journal-id>
<journal-id journal-id-type="iso-abbrev">Schizophr. Res.</journal-id>
<journal-title-group>
<journal-title>Schizophrenia research</journal-title>
</journal-title-group>
<issn pub-type="ppub">0920-9964</issn>
<issn pub-type="epub">1573-2509</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26827128</article-id>
<article-id pub-id-type="pmc">4963306</article-id>
<article-id pub-id-type="doi">10.1016/j.schres.2016.01.039</article-id>
<article-id pub-id-type="manuscript">NIHMS755550</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Understanding the genetic liability to schizophrenia through the neuroepigenome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Fullard</surname>
<given-names>John F.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Halene</surname>
<given-names>Tobias B.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Giambartolomei</surname>
<given-names>Claudia</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Haroutunian</surname>
<given-names>Vahram</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Akbarian</surname>
<given-names>Schahram</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Roussos</surname>
<given-names>Panos</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA</aff>
<aff id="A2"><label>2</label>Department of Genetics and Genomic Science and Institute for Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA</aff>
<aff id="A3"><label>3</label>Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA</aff>
<aff id="A4"><label>4</label>Mental Illness Research, Education, and Clinical Center (VISN 3), James J. Peters VA Medical Center, Bronx, NY, USA</aff>
<author-notes>
<corresp id="FN1">Correspondence: Dr. Panos Roussos, Icahn School of Medicine at Mount Sinai, Department of Psychiatry and Department of Genetics and Genomic Science and Institute for Multiscale Biology, One Gustave L. Levy Place, New York, NY, 10029, USA, <email>Panagiotis.roussos@mssm.edu</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p>
<bold>Conflict of interest:</bold>
</p>
<p>The authors whose names are listed immediately below certify that they have NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakersâ€™ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>2</day>
<month>2</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>27</day>
<month>1</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>11</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>11</month>
<year>2017</year>
</pub-date>
<volume>177</volume>
<issue>1-3</issue>
<fpage>115</fpage>
<lpage>124</lpage>
<!--elocation-id from pubmed: 10.1016/j.schres.2016.01.039-->
<abstract>
<p id="P2">The Psychiatric Genomics Consortium-Schizophrenia Workgroup (PGC-SCZ) recently identified 108 loci associated with increased risk for schizophrenia (SCZ). The vast majority of these variants reside within non-coding sequences of the genome and are predicted to exert their effects by affecting the mechanism of action of <italic>cis</italic> regulatory elements (CREs), such as promoters and enhancers. Although a number of large-scale collaborative efforts (e.g. ENCODE) have achieved a comprehensive mapping of CREs in human cell lines or tissue homogenates, it is becoming increasingly evident that many risk-associated variants are enriched for expression Quantitative Trait Loci (eQTLs) and CREs in specific tissues or cells. As such, data derived from previous research endeavors may not capture fully cell-type and/or region specific changes associated with brain diseases. Coupling recent technological advances in genomics with cell-type specific methodologies, we are presented with an unprecedented opportunity to better understand the genetics of normal brain development and function and, in turn, the molecular basis of neuropsychiatric disorders. In this review, we will outline ongoing efforts towards this goal and will discuss approaches with the potential to shed light on the mechanism(s) of action of cell-type specific <italic>cis</italic> regulatory elements and their putative roles in disease, with particular emphasis on understanding the manner in which the epigenome and CREs influence the etiology of SCZ.</p>
</abstract>
<kwd-group>
<kwd>Postmortem</kwd>
<kwd>brain</kwd>
<kwd>gene expression</kwd>
<kwd>chromatin</kwd>
<kwd>epigenetics</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>